Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2005
11/02/2005CN1689645A Combination therapies for B-cell lynphomas comprising administration of anti-CD20 antibody
11/02/2005CN1689644A Combination therapies for B-cell lynphomas comprising administration of anti-CD20 antibody
11/02/2005CN1689643A Lactoferrin chewing tablet and preparation method thereof
11/02/2005CN1689642A Purposes of parathyroid hormone
11/02/2005CN1689641A Non-injection preparation of growth hormone and purpose thereof
11/02/2005CN1689640A Purposes of epididymis characteristic antibiotic peptide Bin1b in spermiotiliosis
11/02/2005CN1689639A Tannalbin rapid disintegration preparation and preparing method thereof
11/02/2005CN1225481C Recombinant fusion resisting tumour attack and transfer
11/02/2005CN1225473C Method of preparing cyclic vasoactive peptides
11/02/2005CN1225472C 5-membered ring compounds
11/02/2005CN1225471C Compounds with growth hormone releasing properties
11/01/2005US6960657 Mutant polypeptide; side effect reduction
11/01/2005US6960652 Used to produce immunotoxins (ITs) and cytokines with a reduced ability to promote vascular leak syndrome (VLS)
11/01/2005US6960651 TANGO 332 polypeptides
11/01/2005US6960650 Nucleotide sequences coding proteins for use in the treatment of tumors
11/01/2005US6960648 Peptide transporters that specifically target certain cell types for the delivery of drugs and therapeutic agents
11/01/2005US6960646 Cyclic peptides as potent and selective melanocortin-4 receptors agonists
11/01/2005US6960597 Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
11/01/2005US6960575 Thiazine derivatives
11/01/2005US6960570 Compositions and methods for the therapy and diagnosis of lung cancer
11/01/2005US6960569 Hepatitis C virus non-structural NS3/4A fusion gene
11/01/2005US6960567 Forming an intermediate compound N-((2S)- thiobenzoyl-4 (1,5,5-trimethylhydantoinyl)butanoyl)-L-leucyl-L- tert-leucine N-methylamide by an improved process that substantially reduces the presence of contaminants in the
11/01/2005US6960566 peptide or polypeptide binding to a selectin, blocking binding between selectin and a Lewis SA-Lea or SA-LeX antigen.
11/01/2005US6960565 Compound for inhibiting the influx of polymorphonuclear leukocytes (PMNS) in a tissue, its selection, pharmaceutical compositions and use
11/01/2005US6960564 Echinocandin pharmaceutical formulations containing micelle-forming surfactants
11/01/2005US6960563 Spontaneous emulsions containing cyclosporine
11/01/2005US6960562 Administering to said mammal a megakaryocyte stimulating factor (MSF) or alternatively spliced variant to reduce a symptom of osteoarthritis in a mammal
11/01/2005US6960561 Polypeptide mixture containing preservative, surfactant and stabilizer
11/01/2005US6960559 Neurite growth regulatory factors
11/01/2005US6960558 Method of screening for anti-obesity agents using ciliary neutrophic factor receptor
11/01/2005US6960471 For cancer diagnostics
11/01/2005US6960469 Adenoviral vectors encoding an antibody fused to a CD4 extracellular domain
11/01/2005US6960444 Transcriptional mediators of blood vessel development and endothelial differentiation
11/01/2005US6960443 Anticancer, antitumor agents; monoclonal antibodies; genetic engineered protein
11/01/2005US6960441 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of cancer, inflammation and infections; for use as cosmetic, pesticide and antibiotic
11/01/2005US6960440 Nucleotide sequences coding polypeptide for use in the treatment of nervous system disorders
11/01/2005US6960431 Inhibiting viral propagation and treating viral infection are provided which include administering to cells infected with viruses a therapeutic peptide or a derivative thereof and peptide associated with a transporter that is capable of
11/01/2005US6960430 Screening methods for compounds useful in the regulation of cell proliferation
11/01/2005US6960429 Inhibition of viral gene activities
11/01/2005US6960355 Modified amino acid compounds useful in delivery of active agents
11/01/2005US6960352 Compositions and methods for producing vascular occlusion using a solid-phase platelet binding agent
11/01/2005US6960351 Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
11/01/2005US6960343 Nucleotide sequences coding polypeptide for use in the treatment of necrosis, septic shock and inflammation
11/01/2005US6960337 Methods and compositions for treating benign gynecological disorders
11/01/2005CA2372639C Deuterated cyclosporine analogs and their use as immunomodulating agents
11/01/2005CA2216371C Novel "burst-free" sustained release poly-(lactide/glycolide) microspheres
10/2005
10/30/2005CA2507566A1 Carnobacterium divergens m35 and bacteriocin produced therefrom
10/29/2005WO2006126982A2 Nuclease resistant external guide sequences for treating inflammatory and viral related respiratory diseases
10/29/2005CA2564988A1 Nuclease resistant external guide sequences for treating inflammatory and viral related respiratory diseases
10/27/2005WO2005101021A1 Diagnostics and therapeutics for diseases associated with g protein-coupled adrenergic alpha-1d-receptor (adra1d)
10/27/2005WO2005101012A1 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor, familiy c, group 5, member b (gprc5b)
10/27/2005WO2005100987A1 Novel ligand of g protein coupled receptor protein and use thereof
10/27/2005WO2005100570A1 Earthworm fribrinolytic enzyme gene, genetic engineering strains, and the construction and usages thereof
10/27/2005WO2005100567A1 Gene encoding guanine nucleotide exchange factor and its gene product
10/27/2005WO2005100563A1 Follistatin mutant polypeptide
10/27/2005WO2005100558A1 Cd40 ligand mutant and utilization of the same
10/27/2005WO2005100392A2 Treatment of neuropathic pain with zinc finger proteins
10/27/2005WO2005100389A1 Osteoblast growth factor
10/27/2005WO2005100388A1 Production of insulinotropic peptides
10/27/2005WO2005100385A2 Compounds that block the c5a receptor and their use in therapy
10/27/2005WO2005100384A2 Ai-2 compounds and analogs based on salmonella typhimurium lsrb structure
10/27/2005WO2005100382A1 Vertebrate peptide modulators of lipid metabolism
10/27/2005WO2005100380A1 Antibacterial amide macrocycles ii
10/27/2005WO2005099774A2 Diagnosis and treatment of myeloid and lymphoid cell cancers
10/27/2005WO2005099773A1 Use of erythropoietin for treatment of cancer
10/27/2005WO2005099769A2 Novel g-csf conjugates
10/27/2005WO2005099767A1 Use of glycerol dipalmitostearate for improving the bioavailability of protein active ingredients in subcutaneous or intramuscular injectable formulations
10/27/2005WO2005099758A2 Injectable bioartificial tissue matrix
10/27/2005WO2005099749A2 Methods for controlling angiogenesis and cell proliferation
10/27/2005WO2005099748A1 Recombinant lysosomal enzymes comprising a glycosylation pattern typical of ciliates for treatment
10/27/2005WO2005099747A1 Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6
10/27/2005WO2005099746A1 Method for modulating appetite
10/27/2005WO2005099745A2 Gcp-170 fusion proteins and uses thereof
10/27/2005WO2005099744A1 Annexin v for preventing atherothrombois and plaque rupture
10/27/2005WO2005099743A1 Novel use of a polypeptide comprising fas-1 domain
10/27/2005WO2005099742A1 Vascular network forming agent
10/27/2005WO2005099741A1 Remedy for motoneuron diseases
10/27/2005WO2005099740A1 Use of peptidic compounds for the prophylaxis and treatment of chronic headache
10/27/2005WO2005099739A1 Oxygenated dibenzo-alpha-pyrone chromoproteins
10/27/2005WO2005099485A1 Health food, process for producing the same and dried matter or extract
10/27/2005WO2005099337A2 Therapeutic peptides
10/27/2005WO2005087725A3 Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
10/27/2005WO2005079834A9 Use of dmbt1 for capturing sulphate and phosphate group exposing agents
10/27/2005WO2005078097A3 RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (Multifunctional siNA)
10/27/2005WO2005075630A3 New acylglycerol acyltransferase-like proteins dc4 and uses thereof
10/27/2005WO2005072045A3 The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
10/27/2005WO2005066337A3 Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation
10/27/2005WO2005066205A3 Antiviral compositions which inhibit paramyxovirus infection
10/27/2005WO2005063966A3 Method for in vitro differentiation of neuronal stem cells or cells derived from neuronal stem cells
10/27/2005WO2005060375A3 Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like protein
10/27/2005WO2005053728A3 Obesity-associated proteins and the use thereof in therapy and diagnosis
10/27/2005WO2005052000A3 Anti-il-20 antibodies and binding partners and methods of using in inflammation
10/27/2005WO2005051451A8 Electrical devices and anti-scarring agents
10/27/2005WO2005033311A3 Methods for modulating neuronal responses using inhibitors of ampa receptor endocytosis
10/27/2005WO2005009225A3 Tissue adhesive sealant
10/27/2005WO2005007853A3 Inhibition of apoptosis-specific elf-5a (“eif-5a1”) with antisense oligonucleotides and sirnas as anti-inflammatory therapeutics
10/27/2005WO2004100890A3 Rage g82s-related methods and compositions for treating inflammatory disorders
10/27/2005WO2004081030A8 Peptides selectively lethal to malignant and transformed mammalian cells
10/27/2005WO2004073648A3 Composition and methods for inhibiting cell survival
10/27/2005WO2004072284A8 Modulation of insulin like growth factor i receptor expression
1 ... 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 ... 3163